Showing results (21-30 of 208) with videos related to
Sort By:
Pageof 21
Expert Opinion on Investigational Drugs|August 10, 2019
TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetesAoife Egan, Adrian VellaClinical Reviews in Bone and Mineral Metabolism|June 26, 2015
Osteocalcin and the Regulation of Glucose MetabolismAdrian Vella, Rajiv KumarDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetesGalina Smushkin, Adrian VellaCurrent Opinion in Clinical Nutrition and Metabolic Care|May 18, 2010
Genetics of type 2 diabetesGalina Smushkin, Adrian VellaPersonalized Medicine|February 18, 2010
Personalized pharmacotherapy for Type 2 diabetes mellitusAirani Sathananthan, Adrian VellaPhysiology (Bethesda, Md.)|December 9, 2016
Obstacles to Translating Genotype-Phenotype Correlates in Metabolic DiseaseAnu Sharma, Adrian VellaExpert Opinion on Pharmacotherapy|April 22, 2008
Pharmacogenetics: potential role in the treatment of diabetes and obesityAdrian Vella, Michael CamilleriReviews in Endocrine & Metabolic Disorders|May 10, 2014
Effects of GLP-1 on appetite and weightMeera Shah, Adrian VellaEuropean Journal of Endocrinology|April 7, 2017
MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemiaNana Esi Kittah, Adrian VellaMetabolic Syndrome and Related Disorders|July 12, 2018
What Can Diabetes-Associated Genetic Variation in TCF7L2 Teach Us About the Pathogenesis of Type 2 Diabetes?J D Adams, Adrian VellaPageof 21